Piramal Pharma Limited (NSE:PPLPHARMA) — Market Cap & Net Worth
Market Cap & Net Worth: Piramal Pharma Limited (PPLPHARMA)
Piramal Pharma Limited (NSE:PPLPHARMA) has a market capitalization of $2.40 Billion (Rs221.50 Billion) as of June 17, 2026. Listed on the NSE stock exchange, this India-based company holds position #5724 globally and #250 in its home market, demonstrating a 0.26% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Piramal Pharma Limited's stock price Rs167.20 by its total outstanding shares 1324744010 (1.32 Billion). Review Piramal Pharma Limited (PPLPHARMA) total liabilities to assess the company's total debt and financial obligations.
Piramal Pharma Limited Market Cap History: 2022 to 2026
Piramal Pharma Limited's market capitalization history from 2022 to 2026. Data shows change from $1.64 Billion to $2.40 Billion (-3.42% CAGR).
Index Memberships
Piramal Pharma Limited is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY SMALLCAP 100
NIFSMCP100
|
$195.69 Billion | 1.22% | #31 of 100 |
|
NIFTY 500
NIFTY500
|
$3.10 Trillion | 0.08% | #229 of 500 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.13 Trillion | 0.21% | #144 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.18 Trillion | 0.08% | #223 of 750 |
|
NIFTY SMALLCAP 250
NISM250
|
$384.39 Billion | 0.62% | #48 of 250 |
|
NIFTY SMALLCAP 50
NISM50
|
$116.75 Billion | 2.05% | #21 of 50 |
Weight: Piramal Pharma Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Piramal Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Piramal Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
Piramal Pharma Limited's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.64 Billion | $64.72 Billion | $3.76 Billion | 0.03x | 0.44x |
| 2023 | $1.99 Billion | $70.32 Billion | -$1.86 Billion | 0.03x | N/A |
| 2024 | $3.81 Billion | $81.06 Billion | $178.20 Million | 0.05x | 21.41x |
| 2025 | $2.47 Billion | $90.61 Billion | $911.30 Million | 0.03x | 2.71x |
| 2026 | $2.40 Billion | $88.69 Billion | -$3.26 Billion | 0.03x | N/A |
Competitor Companies of PPLPHARMA by Market Capitalization
Companies near Piramal Pharma Limited in the global market cap rankings as of June 17, 2026.
Key companies related to Piramal Pharma Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #512 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #613 globally with a market cap of $44.69 Billion USD ( CN¥305.43 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #512 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.41 |
| #613 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.69 Billion | CN¥47.88 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Piramal Pharma Limited Historical Marketcap From 2022 to 2026
Between 2022 and today, Piramal Pharma Limited's market cap moved from $1.64 Billion to $ 2.40 Billion, with a yearly change of -3.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs2.40 Billion | -2.91% |
| 2025 | Rs2.47 Billion | -35.32% |
| 2024 | Rs3.81 Billion | +91.89% |
| 2023 | Rs1.99 Billion | +21.11% |
| 2022 | Rs1.64 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Piramal Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.40 Billion USD |
| MoneyControl | $2.40 Billion USD |
| MarketWatch | $2.40 Billion USD |
| marketcap.company | $2.40 Billion USD |
| Reuters | $2.40 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, i… Read more